medroxyprogesterone has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogh, KK; Brendle, SA; Christensen, ND; Cladel, NM; Cooper, T; Hu, J; Li, JJ; Shearer, DA; Walter, V | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Arai, T; Jobo, T; Kawaguchi, M; Kuramoto, H | 1 |
| Bennett, SK; Heldman, AW; Herrington, DM; Ouyang, P; Stewart, KJ; Tardif, JC; Tayback, MA; Thompson, PD; Walsh, MN; Wang, NY | 1 |
1 review(s) available for medroxyprogesterone and Disease Exacerbation
| Article | Year |
|---|---|
[Borderline lesions in the endometrium].
Topics: Cell Transformation, Neoplastic; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Medroxyprogesterone; Progesterone Congeners | 2004 |
1 trial(s) available for medroxyprogesterone and Disease Exacerbation
| Article | Year |
|---|---|
Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries.
Topics: Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Medroxyprogesterone; Middle Aged; Postmenopause; Retrospective Studies; Saphenous Vein; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2006 |
2 other study(ies) available for medroxyprogesterone and Disease Exacerbation
| Article | Year |
|---|---|
Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model.
Topics: Animals; Contraceptive Agents; Disease Models, Animal; Disease Progression; Estradiol; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mice; Mice, Nude; Papillomavirus Infections | 2022 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |